Stock Research: Bachem

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Bachem

SWX:BANB CH1176493729
51
  • Value
    96
  • Growth
    29
  • Safety
    Safety
    32
  • Combined
    60
  • Sentiment
    54
  • 360° View
    360° View
    51
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Bachem Holding AG is a biochemical company providing services to the pharmaceutical and biotechnology industries. It focuses on the process development and manufacturing of peptides and organic molecules as active pharmaceutical ingredients (APIs). It operates under the Bachem and Clinalfa brands. The company operates in Switzerland and the United States. In the last fiscal year, the company had a market cap of $5,320 million, profits of $201 million, and revenue of $667 million, with 2207 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 51 (better than 51% compared with alternatives), overall professional sentiment and financial characteristics for the stock Bachem are above average. The 360° View is based on consolidating four consolidated indicators, with half below and half above average for Bachem. The consolidated Sentiment Rank has a good rank of 54, which means that professional investors are more optimistic about the stock than for 54% of alternative investment opportunities. It also rates well regarding its financing structure, with the consolidated Safety Rank at 96 or better than 96% of its peers when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the stock is expensive and expects low growth. The consolidated Value Rank is only 32, meaning that the share price of Bachem is on the high side, compared with indicators such as revenues, profits, and invested capital. The company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth,and stock returns, with its Growth Rank at 29. ...read more

more
Index
SDG 12
SDG 3
SDG 4
SDG 8
SPI
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 10-Sep-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
32 47 45 35
Growth
29 24 83 99
Safety
Safety
96 100 98 90
Sentiment
54 75 13 12
360° View
360° View
51 85 82 73
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
24 5 1 17
Opinions Change
50 62 75 26
Pro Holdings
n/a 80 53 72
Market Pulse
45 87 4 38
Sentiment
54 75 13 12
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
32 47 45 35
Growth
29 24 83 99
Safety Safety
96 100 98 90
Combined
60 78 100 100
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
35 33 30 11
Price vs. Earnings (P/E)
12 13 17 28
Price vs. Book (P/B)
38 40 37 13
Dividend Yield
63 72 63 61
Value
32 47 45 35
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
89 75 80 75
Profit Growth
25 42 56 78
Capital Growth
18 11 95 86
Stock Returns
31 37 35 95
Growth
29 24 83 99
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
94 95 96 49
Refinancing
54 60 59 96
Liquidity
98 100 100 96
Safety Safety
96 100 98 90

Similar Stocks

Discover high‑ranked alternatives to Bachem and broaden your portfolio horizons.

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt.

BUSE:RICHTER
Country: Hungary
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

DKSH

SWX:DKSH
Country: Switzerland
Industry: Research & Consulting
Size: Large
Full Stock Analysis

ALSO

SWX:ALSN
Country: Switzerland
Industry: Technology Distributors
Size: Medium
Full Stock Analysis

Perrigo

NYSE:PRGO
Country: Ireland
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.